The oral delivery of peptides has been a longstanding goal in pharmaceutical development, traditionally considered impossible due to the hostile gastrointestinal environment.
The Challenge of Oral Peptide Delivery
Enzymatic Barriers - **Stomach** — Pepsin cleaves at aromatic residues (pH 1-3) - **Small intestine** — Trypsin, chymotrypsin, elastase - **Brush border** — Aminopeptidases, DPP-IV - Result: <1% of native peptides survive GI transit
Physical Barriers - **Mucus layer** — Traps particles - **Tight junctions** — Block paracellular transport - **Size exclusion** — Peptides too large for passive diffusion - **Hydrophilicity** — Limits transcellular absorption
Successful Strategies
Permeation Enhancers (SNAC Technology)
Sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC)
- **Buffers local pH** — Protects from pepsin
- **Facilitates transcellular transport** — Opens absorption pathway
- **Must be taken fasting** — Food interferes with absorption
Bioavailability: ~0.4-1% (requires higher doses)
Enteric Coatings - Protect peptides through stomach (pH 1-3) - Dissolve in intestine (pH 6-7.4) - Common polymers: Eudragit, HPMC phthalate
Nanocarrier Systems
| Type | Mechanism | Advantages |
|---|---|---|
| Liposomes | Lipid vesicles | Biocompatible |
| Chitosan NPs | Mucoadhesive | Opens tight junctions |
| PLGA NPs | Sustained release | Biodegradable |
| Lipid NPs | Lymphatic uptake | Avoid first-pass |
Protease Inhibitors - Co-administer enzyme inhibitors - Examples: Aprotinin, soybean trypsin inhibitor - Concern: May affect digestion
Ingestible Device Technologies
SOMA (Self-Orienting Millimeter-scale Applicator) - Swallowable capsule - Self-orients to stomach wall - Injects peptide via spring-loaded needle - Developed by MIT/Novo Nordisk
RaniPill® - Capsule transits to small intestine - Needle patch deploys on intestinal wall - Delivers peptide systemically - Phase 2 trials completed
Ingestible Microjet - Uses pressure to inject through intestinal wall - No needle required - Preclinical development
Current Status of Oral Peptide Drugs
| Drug | Peptide | Indication | Technology |
|---|---|---|---|
| Rybelsus® | Semaglutide | Diabetes | SNAC |
| DDAVP® | Desmopressin | Diabetes insipidus | High dose |
| Cyclosporin | Cyclic peptide | Immunosuppression | Natural stability |
The Future
- **Multi-modal approaches** — Combining protection + enhancement
- **Intestinal patches** — Localized delivery
- **Modified peptides** — Designed for oral absorption
- **Closed-loop devices** — Glucose-responsive insulin delivery